Literature DB >> 30165580

Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.

Sanjiv J Shah1, Carolyn S P Lam2,3, Sara Svedlund4, Antti Saraste5, Camilla Hage6, Ru-San Tan2, Lauren Beussink-Nelson1, Ulrika Ljung Faxén6, Maria Lagerström Fermer7, Malin A Broberg7, Li-Ming Gan7,8,9, Lars H Lund6.   

Abstract

Aims: To date, clinical evidence of microvascular dysfunction in patients with heart failure (HF) with preserved ejection fraction (HFpEF) has been limited. We aimed to investigate the prevalence of coronary microvascular dysfunction (CMD) and its association with systemic endothelial dysfunction, HF severity, and myocardial dysfunction in a well defined, multi-centre HFpEF population. Methods and results: This prospective multinational multi-centre observational study enrolled patients fulfilling strict criteria for HFpEF according to current guidelines. Those with known unrevascularized macrovascular coronary artery disease (CAD) were excluded. Coronary flow reserve (CFR) was measured with adenosine stress transthoracic Doppler echocardiography. Systemic endothelial function [reactive hyperaemia index (RHI)] was measured by peripheral arterial tonometry. Among 202 patients with HFpEF, 151 [75% (95% confidence interval 69-81%)] had CMD (defined as CFR <2.5). Patients with CMD had a higher prevalence of current or prior smoking (70% vs. 43%; P = 0.0006) and atrial fibrillation (58% vs. 25%; P = 0.004) compared with those without CMD. Worse CFR was associated with higher urinary albumin-to-creatinine ratio (UACR) and NTproBNP, and lower RHI, tricuspid annular plane systolic excursion, and right ventricular (RV) free wall strain after adjustment for age, sex, body mass index, atrial fibrillation, diabetes, revascularized CAD, smoking, left ventricular mass, and study site (P < 0.05 for all associations). Conclusions: PROMIS-HFpEF is the first prospective multi-centre, multinational study to demonstrate a high prevalence of CMD in HFpEF in the absence of unrevascularized macrovascular CAD, and to show its association with systemic endothelial dysfunction (RHI, UACR) as well as markers of HF severity (NTproBNP and RV dysfunction). Microvascular dysfunction may be a promising therapeutic target in HFpEF.

Entities:  

Mesh:

Year:  2018        PMID: 30165580      PMCID: PMC6927847          DOI: 10.1093/eurheartj/ehy531

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  39 in total

1.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

2.  Light cigarette smoking impairs coronary microvascular functions as severely as smoking regular cigarettes.

Authors:  Hakan Gullu; Mustafa Caliskan; Ozgur Ciftci; Dogan Erdogan; Semra Topcu; Erkan Yildirim; Aylin Yildirir; Haldun Muderrisoglu
Journal:  Heart       Date:  2007-05-13       Impact factor: 5.994

3.  2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.

Authors:  Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2016-12

4.  Reduced Myocardial Flow in Heart Failure Patients With Preserved Ejection Fraction.

Authors:  Kajenny Srivaratharajah; Thais Coutinho; Robert deKemp; Peter Liu; Haissam Haddad; Ellamae Stadnick; Ross A Davies; Sharon Chih; Girish Dwivedi; Ann Guo; George A Wells; Jordan Bernick; Robert Beanlands; Lisa M Mielniczuk
Journal:  Circ Heart Fail       Date:  2016-07       Impact factor: 8.790

5.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Sherif F Nagueh; Otto A Smiseth; Christopher P Appleton; Benjamin F Byrd; Hisham Dokainish; Thor Edvardsen; Frank A Flachskampf; Thierry C Gillebert; Allan L Klein; Patrizio Lancellotti; Paolo Marino; Jae K Oh; Bogdan Alexandru Popescu; Alan D Waggoner
Journal:  J Am Soc Echocardiogr       Date:  2016-04       Impact factor: 5.251

6.  Microvascular endothelial dysfunction in heart failure with preserved ejection fraction.

Authors:  Carolyn S P Lam; Lars H Lund
Journal:  Heart       Date:  2016-02-15       Impact factor: 5.994

7.  Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.

Authors:  Viviany R Taqueti; Scott D Solomon; Amil M Shah; Akshay S Desai; John D Groarke; Michael T Osborne; Jon Hainer; Courtney F Bibbo; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli
Journal:  Eur Heart J       Date:  2018-03-07       Impact factor: 29.983

8.  Association of low-grade albuminuria with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network (HyperGEN) study.

Authors:  Daniel H Katz; Senthil Selvaraj; Frank G Aguilar; Eva E Martinez; Lauren Beussink; Kwang-Youn A Kim; Jie Peng; Jin Sha; Marguerite R Irvin; John H Eckfeldt; Stephen T Turner; Barry I Freedman; Donna K Arnett; Sanjiv J Shah
Journal:  Circulation       Date:  2013-09-27       Impact factor: 29.690

9.  Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction.

Authors:  Barry A Borlaug; Wissam A Jaber; Steve R Ommen; Carolyn S P Lam; Margaret M Redfield; Rick A Nishimura
Journal:  Heart       Date:  2011-04-08       Impact factor: 5.994

10.  Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction.

Authors:  Michael A Burke; Daniel H Katz; Lauren Beussink; Senthil Selvaraj; Deepak K Gupta; Justin Fox; Sudarsana Chakrabarti; Andrew J Sauer; Jonathan D Rich; Benjamin H Freed; Sanjiv J Shah
Journal:  Circ Heart Fail       Date:  2013-12-23       Impact factor: 8.790

View more
  120 in total

Review 1.  Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

Authors:  Fayez El Shear
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

2.  Myocardial Energetics in Heart Failure With Preserved Ejection Fraction.

Authors:  Omar F AbouEzzeddine; Bradley J Kemp; Barry A Borlaug; Brian P Mullan; Atta Behfar; Sorin V Pislaru; Marat Fudim; Margaret M Redfield; Panithaya Chareonthaitawee
Journal:  Circ Heart Fail       Date:  2019-10-15       Impact factor: 8.790

3.  Bortezomib induced pulmonary toxicity: a case report and review of the literature.

Authors:  Burcin Saglam; Hakan Kalyon; Murat Ozbalak; Serdar Ornek; Siran Keske; Levent Tabak; Nahit Cakar; Handan Zeren; Saide Aytekin; Yasemin Bolukbasi; Burhan Ferhanoglu
Journal:  Am J Blood Res       Date:  2020-12-15

Review 4.  The Role of Echocardiography in Heart Failure with Preserved Ejection Fraction: What Do We Want from Imaging?

Authors:  Masaru Obokata; Yogesh N V Reddy; Barry A Borlaug
Journal:  Heart Fail Clin       Date:  2019-02-02       Impact factor: 3.179

Review 5.  Macrophages in Heart Failure with Reduced versus Preserved Ejection Fraction.

Authors:  Matthew DeBerge; Sanjiv J Shah; Lisa Wilsbacher; Edward B Thorp
Journal:  Trends Mol Med       Date:  2019-02-05       Impact factor: 11.951

Review 6.  Heart Failure With Preserved Ejection Fraction In Perspective.

Authors:  Marc A Pfeffer; Amil M Shah; Barry A Borlaug
Journal:  Circ Res       Date:  2019-05-24       Impact factor: 17.367

Review 7.  Cardiorenal syndrome in heart failure with preserved ejection fraction-an under-recognized clinical entity.

Authors:  Akanksha Agrawal; Mario Naranjo; Napatt Kanjanahattakij; Janani Rangaswami; Shuchita Gupta
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

8.  Frequency of Coronary Microvascular Dysfunction and Diffuse Myocardial Fibrosis (Measured by Cardiovascular Magnetic Resonance) in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.

Authors:  Adrián I Löffler; Jonathan A Pan; Pelbreton C Balfour; Peter W Shaw; Yang Yang; Moiz Nasir; Daniel A Auger; Frederick H Epstein; Christopher M Kramer; Li-Ming Gan; Michael Salerno
Journal:  Am J Cardiol       Date:  2019-08-22       Impact factor: 2.778

9.  Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.

Authors:  Jasper Tromp; Camilla Hage; Wouter Ouwerkerk; Sandra Sanders-van Wijk; Sara Svedlund; Antti Saraste; Ulrika Ljung Faxén; Maria Lagerstrom Fermer; Li-Ming Gan; Lars H Lund; Sanjiv J Shah; Carolyn S P Lam
Journal:  Circulation       Date:  2019-10-14       Impact factor: 29.690

Review 10.  Sex Differences in Cardiovascular Aging and Heart Failure.

Authors:  Andrew Oneglia; Michael D Nelson; C Noel Bairey Merz
Journal:  Curr Heart Fail Rep       Date:  2020-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.